Chien Chung Wei

Eden Biologics, Inc. is engaged in the manufacture and sale of bio-pharmaceuticals products. It offers cell line cloning, antibody cloning, monoclonal antibody, cell line development, master and working cell banks, cell culture process development, purification process development, formulation development, and analytical assays. The company was founded on June 14, 2012 and is headquartered in Zhupei, Taiwan.

KPCB China Fund II LP seeks investment opportunities in companies located in China. The fund focuses on companies operating in the fields of health technology, industrial services, and technology services sectors.. It provides financing for seed, early and later-stage capital requirements.

Chime Biologics Ltd. is a leading Contract Development and Manufacturing Organization (CDMO) that provides customer-centric and cost-effective outsourcing services for biopharmaceutical development and manufacturing. The company is based in Wuhan, China, and its world's first GE Kubio facility is located at Wuhan's Bio-Lake Biotech Industry Development Zone, with a clear path to expand the total capacity up to 140,000+ liters in the near future. The Chinese company has introduced the world's first modular biopharmaceutical plant, Kubio, which empowers its partners' success in biologics from cell line development to commercial manufacturing. Chime Biologics is committed to making cutting-edge biomedicines affordable and accessible to all patients, fulfilling its commitment to human health. Chime Biologics is ISO 14001:2015 and ISO 45001:2018 certified and has been providing customers with clinical materials for pre-clinical and clinical stages worldwide since 2016.